Author

David E. Bernstein 1

1 North Shore University Hospital,Manhasset,United States

99.7% SUSTAINED VIROLOGIC RESPONSE RATE IN 369 HCV GENOTYPE 1B-INFECTED PATIENTS TREATED WITH LABEL-RECOMMENDED REGIMEN OF OMBITASVIR/PARITAPREVIR/R AND DASABUVIR WITH OR WITHOUT RIBAVIRIN

Jean-François Dufour, Heiner Wedemeyer, David E. Bernstein, Massimo Colombo, Manuel Romero-Gomez, Nancy Reau, Roger Trinh, Wangang Xie, Jeffrey Enejosa, Daniel E. Cohen, Marisol Martinez, Ira M. Jacobson

ADHERENCE TO PRESCRIBED DOSES OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN THE PHASE 3 PEARL-II, PEARL-III, AND PEARL-IV TRIALS

David E. Bernstein, Rui Tato Marinho, Daniel E. Cohen, Fritz Bredeek, Ferenc Schneider, Gunnar Norkrans, Manuela Curescu, Michael Bennett, Marina Maevskaya, Jeffrey Fessel, Yan Luo, Jeffrey Enejosa

LOW INCIDENCE OF HYPERBILIRUBINAEMIA EVENTS WITH ABT-450/R/OMBITASVIR AND DASABUVIR WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE-1 INFECTED PATIENTS

Manuel Romero-Gomez, Rui Tato Marinho, Ramon Vila, David E. Bernstein, Federico Rodriguez-Perez, Tarek Hassanein, K. Reddy, Naoky Tsai, Sandra Lovell, Jeffrey Enejosa, Yan Luo, Daniel E. Cohen, Marcos Pedrosa, Massimo Colombo

MANAGEMENT OF HAEMOGLOBIN DECREASE IN PATIENTS TREATED WITH ABT-450/RITONAVIR/OMBITASVIR AND DASABUVIR WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE 1-INFECTED PATIENTS

Daniel Forton, Hendrik Reesink, David E. Bernstein, Thomas Sepe, John Vierling, William King, Yiran Hu, Jeffrey Enejosa, Daniel E. Cohen, Yan Luo, Marcos Pedrosa, Peter Ferenci

Item 1 - 4 / 4
1